Eton Pharmaceuticals Current Ratio 2018-2021 | ETON

Eton Pharmaceuticals current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Eton Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.00B 9.36
2021-03-31 $0.03B $0.00B 9.46
2020-12-31 $0.03B $0.00B 6.51
2020-09-30 $0.01B $0.00B 3.04
2020-06-30 $0.01B $0.00B 4.68
2020-03-31 $0.02B $0.00B 7.48
2019-12-31 $0.02B $0.00B 7.65
2019-09-30 $0.01B $0.00B 10.94
2019-06-30 $0.02B $0.00B 11.48
2019-03-31 $0.02B $0.00B 5.89
2018-12-31 $0.03B $0.00B 13.59
2018-09-30 $0.01B $0.00B 5.68
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.123B $0.000B
Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71